EXEL
Companies
NASDAQ
Exelixis Inc.
Health Care
$40.73
+$7.43 (+22.31%)
Price Chart
Overview
About EXEL
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Market Cap
$6.4B
Volume
202.1M
Avg. Volume
131.9M
P/E Ratio
26.094118
Dividend Yield
0.00%
Employees
1.4K
Company Information
Risk & Correlation Analysis
Market Correlation
0.63
Low Correlation
Volatility
Medium (0.35)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, EXEL shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$6.4B
Volume202.1M
P/E Ratio26.09
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
October 30, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025